Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097214
Status:
COMPLETED
Last Update Posted:
2010-04-09
First Post:
2004-11-18
Brief Title:
Carboplatin Plus Cetuximab for Treatment of Stage IIIBIV Non-Small Cell Lung Cancer NSCLC
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Organization Data
Organization:
Eli Lilly and Company
Class:
INDUSTRY
Study ID:
CA225-081
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eli Lilly and Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Chief Medical Officer
Old Organization:
ImClone LLC
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |